Ebihara K, Nishikawa K, Shibasaki C, Takahashi K, Matsuda A
Research Laboratories, Pharmaceuticals Group, Nippon Kayaku Co., Ltd.
Jpn J Antibiot. 1987 Sep;40(9):1566-70.
Antitumor activity of peplomycin (PEP) against 7,12-dimethylbenz(a)anthracene (DMBA)-induced rat mammary tumors was compared with activities of bleomycin (BLM) and doxorubicin (adriamycin, ADM). Drugs were administered subcutaneously 3 times weekly (24 times in total) starting on 75 days after an intravenous administration of DMBA. PEP strongly inhibited the growth of mammary tumors detected at the start of the treatment, and some of the tumors disappeared and regressed upon the administration of PEP. The number of stable tumors was larger and the number of progressed tumors smaller in the PEP-treated group than in the control group. Moreover, PEP exhibited strong growth inhibitory effect with slight delay of tumor appearance against mammary tumors appeared during the treatment period. These antitumor effects of PEP were greater than those of BLM, a parent compound of PEP, and almost comparable to those of ADM.
将培普利霉素（PEP）对7,12-二甲基苯并(a)蒽（DMBA）诱导的大鼠乳腺肿瘤的抗肿瘤活性与博来霉素（BLM）和多柔比星（阿霉素，ADM）的活性进行了比较。在静脉注射DMBA 75天后开始，每周皮下给药3次（共24次）。PEP强烈抑制治疗开始时检测到的乳腺肿瘤的生长，并且一些肿瘤在给予PEP后消失并消退。与对照组相比，PEP治疗组中稳定肿瘤的数量更多，进展肿瘤的数量更少。此外，PEP对治疗期间出现的乳腺肿瘤表现出强烈的生长抑制作用，且肿瘤出现略有延迟。PEP的这些抗肿瘤作用大于其母体化合物BLM的作用，几乎与ADM的作用相当。
